Genocea Biosciences, Inc.

Equities

GNCAQ

US3724274010

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 10:09:18 2024-04-23 am EDT			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	0.00%

2023	Genocea Biosciences, Inc. Went Out of Business	CI
2023	Liquidation Plan Approved for Genocea Biosciences, Inc.	CI

GENOCEA BIOSCIENCES, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)

June 01, 2022 at 04:11 pm EDT

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 25, 2022, Dr. Ali Behbahani notified Genocea Biosciences, Inc. (the "Company") of his desire to resign from the Board of Directors (the "Board") of the Company, effective immediately. Dr. Behbahani has served on the Board since 2018. Dr. Behbahani's resignation was not a result of or caused by any disagreement with the Company.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

Latest news about Genocea Biosciences, Inc.

Genocea Biosciences, Inc. Went Out of Business	23-05-19	CI
Liquidation Plan Approved for Genocea Biosciences, Inc.	23-05-11	CI
First Amended Disclosure Statement Filed by Genocea Biosciences, Inc.	23-03-21	CI
Disclosure Statement Approved for Genocea Biosciences, Inc.	23-03-21	CI
Joint Liquidation Plan and DIsclosure Statement Filed by Genocea Biosciences, Inc.	23-02-09	CI
Motion for Asset Sale Approved for Genocea Biosciences, Inc.	22-09-21	CI
Motion for Asset Sale Approved for Genocea Biosciences, Inc.	22-08-17	CI
Bidding Procedure Approved for Genocea Biosciences, Inc.	22-08-09	CI
Motion for Asset Sale Filed by Genocea Biosciences, Inc.	22-08-04	CI
Genocea Biosciences, Inc. Filed for Bankruptcy	22-07-05	CI
Genocea Biosciences, Inc.(NasdaqCM:GNCA) dropped from S&P TMI Index	22-06-07	CI
Genocea Biosciences, Inc.(NasdaqCM:GNCA) dropped from NASDAQ Composite Index	22-06-02	CI
Genocea Biosciences, Inc. Announces Resignation of Ali Behbahani from Board of Director	22-06-01	CI
US Futures Move Lower Ahead of Durable Goods, Investor Confidence Reports	22-05-25	MT
Top Premarket Gainers	22-05-25	MT
Genocea Biosciences To Wind Down Operations; Shares Fall	22-05-24	MT
Genocea Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-05	CI
Top Premarket Decliners	22-04-29	MT
HC Wainwright Downgrades Genocea Biosciences to Neutral From Buy	22-04-29	MT
Stifel Downgrades Genocea Biosciences to Hold From Buy, Adjusts Price Target to $0.16 From $4.70	22-04-29	MT
Genocea Announces Plan to Explore Strategic Alternatives	22-04-28	CI
Transcript : Genocea Biosciences, Inc. Presents at AACR Annual Meeting 2022, Apr-08-2022 through Apr-14-2022	22-04-11
Baird Adjusts Price Target on Genocea Biosciences to $3 From $8, Keeps Outperform Rating	22-04-11	MT
Wall Street Set for Losses, Surging Treasury Yield Fuels Tech Slump	22-04-11	MT
Top Premarket Gainers	22-04-11	MT

Chart Genocea Biosciences, Inc.

Duration

Period

More charts

Company Profile

Genocea Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing cancer immunotherapies using its proprietary ATLAS platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by next-generation sequencing of that patient's tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, or Inhibigens, that drive pro-tumor immune responses. Its GEN-009 is an investigational neoantigen vaccine delivering adjuvanted synthetic long peptides from ATLAS-identified neoantigens. The Company has a license agreement with Harvard College (Harvard), granting the Company a sublicensable license to one patent family, to develop, make, use, market licensed products, and perform licensed services related to the ATLAS discovery platform.

Sector

Biotechnology & Medical Research

More about the company

	1st Jan change	Capi.
GENOCEA BIOSCIENCES, INC.	0.00%	58
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research